Here’s what you should know:
1. The venture will focus on BioSurfaces’ nanomaterial technology, which uses FDA-approved polymers to produce nanofibrous materials. The material can create “unusual and difficult-to-manufacture shapes.”
2. Takeda is combining its gastroenterology knowledge with BioSurface’s medical device design and nanomaterial knowledge.
3. The companies didn’t disclose terms of the agreement.
4. BioSurfaces President and Chief Technology Officer Matthew Phaneuf said in a release, “We are excited about the opportunity to partner with Takeda … to apply our technology to develop novel therapeutic devices for patients with GI dysfunction[s].”
More articles on gastroenterology:
Olympus ordered to pay up in superbug case & more — 4 GI company key notes
Credentialing for ERCP must be improved
GI center to know: Digestive Health Specialists
